Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Uneven Global Distribution of Theranostics.

World journal of nuclear medicine·2026
Same author

Coastal cancer care: A blueprint to address the unmet needs through place-based research and policy approaches.

Journal of cancer policy·2026
Same author

Is There an Added Value of Dual-Time-Point [<sup>68</sup>Ga]Ga-Fibroblast Activation Protein Inhibitor (FAPI) PET/CT in Differentiating Malignant and Benign Uptake Findings?

Cancers·2026
Same author

[<sup>68</sup>Ga]Ga-PSMA-11 PET/CT for baseline staging of high-risk prostate cancer: A real-world study.

BJUI compass·2026
Same author

<sup>68</sup>Ga-FAPI Avidity in Fat Necrosis and Adrenal Adenoma: Expanding the Spectrum of Benign Pitfalls in Oncologic Imaging.

Molecular imaging and radionuclide therapy·2026
Same author

Diagnostic utility of FAPI PET/CT in radioiodine-refractory thyroid cancer and TENIS syndrome: a systematic review.

Oncology reviews·2026

Related Experiment Video

Updated: Jul 6, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Radiotherapy and theranostics: a Lancet Oncology Commission.

May Abdel-Wahab1, Francesco Giammarile1, Mauro Carrara1

  • 1Division of Human Health, Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria.

The Lancet. Oncology
|October 3, 2024
PubMed
Summary
This summary is machine-generated.

Global access to radiotherapy and theranostics remains unequal. Implementing new technologies like hypofractionation and supporting initiatives can expand treatment availability, especially in low- and middle-income countries (LMICs).

More Related Videos

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Irradiator Commissioning and Dosimetry for Assessment of LQ &alpha; and &beta; Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

Related Experiment Videos

Last Updated: Jul 6, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Irradiator Commissioning and Dosimetry for Assessment of LQ &alpha; and &beta; Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

Area of Science:

  • Oncology
  • Radiotherapy
  • Theranostics

Background:

  • Significant disparities exist in radiotherapy machine availability between high-income and low- and middle-income countries (LMICs).
  • A shortage of trained and credentialed healthcare professionals limits radiotherapy implementation, particularly in LMICs.
  • Access to radiopharmaceutical therapy, beyond iodine-131, is highly variable globally due to supply chain, workforce, and regulatory challenges.

Purpose of the Study:

  • To assess the current global access and availability of radiotherapy and theranostics.
  • To identify and investigate initiatives that can mitigate disparities in radiotherapy access.
  • To propose actions and investments to enhance worldwide access to radiotherapy and theranostics, especially in LMICs.

Main Methods:

  • Analysis of existing data and a global survey on radiotherapy and theranostics availability.
  • Investigation of initiatives such as extended treatment hours, hypofractionation protocols, and new technologies.
  • Assessment of workforce, supply chain, and regulatory factors impacting theranostics access.

Main Results:

  • Implementing hypofractionation in prostate and breast cancer could provide radiotherapy for an additional 2.2 million patients using existing resources.
  • Radioisotope production capacity is a key issue for theranostics, alongside workforce training and regulatory frameworks.
  • Global access to radiopharmaceutical therapy (excluding 131I) shows significant variability.

Conclusions:

  • New technologies and initiatives, like the IAEA's Rays of Hope program, are crucial for improving global radiotherapy access.
  • Investment in radiotherapy and theranostics, supported by governments and international bodies, is essential to reduce cancer burden.
  • Equitable access to radiotherapy and theranostics, particularly in LMICs, can yield significant health and economic benefits.